|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.680 USD | -0.62% |
|
+0.73% | +57.40% |
| 05-15 | ImmuCell Corporation, Q1 2026 Earnings Call, May 15, 2026 | |
| 05-14 | ImmuCell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 0.38 | -3.22 | -7.36 | -1.73 | 3.49 | |||||
Return on Total Capital | 0.39 | -3.35 | -7.72 | -1.83 | 3.69 | |||||
Return On Equity % | -0.26 | -7.92 | -20.86 | -8.21 | -3.81 | |||||
Return on Common Equity | -0.26 | -7.92 | -20.86 | -8.21 | -3.81 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 44.98 | 41.19 | 25.16 | 31.51 | 41.4 | |||||
SG&A Margin | 21.98 | 29.37 | 29.89 | 21.45 | 21.54 | |||||
EBITDA Margin % | 14.13 | 1.02 | -14.33 | 5.49 | 18.73 | |||||
EBITA Margin % | 1.44 | -12.28 | -29.77 | -4.58 | 8.93 | |||||
EBIT Margin % | 1.34 | -12.38 | -29.88 | -4.65 | 8.86 | |||||
Income From Continuing Operations Margin % | -0.41 | -13.43 | -33.05 | -8.14 | -3.76 | |||||
Net Income Margin % | -0.41 | -13.43 | -33.05 | -8.14 | -3.76 | |||||
Net Avail. For Common Margin % | -0.41 | -13.43 | -33.05 | -8.14 | -3.76 | |||||
Normalized Net Income Margin | -0.12 | -8.39 | -20.03 | -4.07 | 4.79 | |||||
Levered Free Cash Flow Margin | -8.5 | -24.8 | -25.81 | 3.88 | 3.61 | |||||
Unlevered Free Cash Flow Margin | -7.52 | -23.67 | -24.24 | 5.06 | 4.53 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.45 | 0.42 | 0.39 | 0.6 | 0.63 | |||||
Fixed Assets Turnover | 0.69 | 0.63 | 0.56 | 0.85 | 1 | |||||
Receivables Turnover (Average Receivables) | 8.57 | 8.34 | 8.86 | 8.9 | 7.69 | |||||
Inventory Turnover (Average Inventory) | 4.09 | 2.39 | 1.89 | 2.43 | 1.98 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 6.42 | 4.56 | 2.73 | 3.41 | 4.26 | |||||
Quick Ratio | 5.09 | 2.47 | 0.76 | 1.72 | 1.82 | |||||
Operating Cash Flow to Current Liabilities | 0.38 | -0.5 | -1.11 | 0.08 | 0.62 | |||||
Days Sales Outstanding (Average Receivables) | 42.59 | 43.77 | 41.2 | 41.14 | 47.47 | |||||
Days Outstanding Inventory (Average Inventory) | 89.34 | 152.57 | 193.32 | 150.52 | 184.54 | |||||
Average Days Payable Outstanding | 20.94 | 19.13 | 19.68 | 18.98 | 17.17 | |||||
Cash Conversion Cycle (Average Days) | 110.99 | 177.21 | 214.83 | 172.68 | 214.83 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 31.54 | 41.08 | 66.78 | 54.87 | 48.77 | |||||
Total Debt / Total Capital | 23.98 | 29.12 | 40.04 | 35.43 | 32.78 | |||||
LT Debt/Equity | 28.71 | 37.55 | 58.49 | 47.86 | 42.5 | |||||
Long-Term Debt / Total Capital | 21.83 | 26.62 | 35.07 | 30.9 | 28.57 | |||||
Total Liabilities / Total Assets | 26.74 | 32.28 | 42.95 | 38.98 | 36.39 | |||||
EBIT / Interest Expense | 0.82 | -6.6 | -10.98 | -2.17 | 4.96 | |||||
EBITDA / Interest Expense | 9.15 | 1.07 | -4.45 | 3.43 | 11.47 | |||||
(EBITDA - Capex) / Interest Expense | 0.86 | -10.33 | -8.43 | 2.61 | 8.93 | |||||
Total Debt / EBITDA | 3.57 | 33.35 | -7.88 | 7.75 | 2.33 | |||||
Net Debt / EBITDA | 0.03 | 17.87 | -7.42 | 5.82 | 1.66 | |||||
Total Debt / (EBITDA - Capex) | 38.16 | -3.47 | -4.16 | 10.19 | 2.99 | |||||
Net Debt / (EBITDA - Capex) | 0.33 | -1.86 | -3.92 | 7.65 | 2.13 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 25.42 | -3.51 | -5.9 | 51.64 | 4.34 | |||||
Gross Profit, 1 Yr. Growth % | 26.13 | -11.64 | -46.63 | 89.89 | 44.13 | |||||
EBITDA, 1 Yr. Growth % | 181.15 | -93.06 | -422.01 | -158.07 | 394.63 | |||||
EBITA, 1 Yr. Growth % | -120.31 | -924.57 | 207.66 | -76.66 | -252.27 | |||||
EBIT, 1 Yr. Growth % | -118.65 | -993.19 | 205.34 | -76.38 | -249.33 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -92.34 | 3.09K | 131.56 | -62.65 | -51.78 | |||||
Net Income, 1 Yr. Growth % | -92.34 | 3.09K | 131.56 | -62.65 | -51.78 | |||||
Normalized Net Income, 1 Yr. Growth % | -97.84 | 6.43K | 194.05 | -69.21 | -199.4 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -92.72 | 3.02K | 132.93 | -64.79 | -54.56 | |||||
Accounts Receivable, 1 Yr. Growth % | 49.95 | -34.73 | 24.27 | 72.56 | -9.34 | |||||
Inventory, 1 Yr. Growth % | 47.67 | 95.42 | 29.37 | -8.95 | 30.29 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 0.1 | 9.4 | 4.93 | -6.96 | -14.9 | |||||
Total Assets, 1 Yr. Growth % | 10.2 | 0.89 | -2.35 | 2.95 | -5.69 | |||||
Tangible Book Value, 1 Yr. Growth % | 15.42 | -6.72 | -17.76 | 10.23 | -1.62 | |||||
Common Equity, 1 Yr. Growth % | 15.25 | -6.74 | -17.73 | 10.1 | -1.68 | |||||
Cash From Operations, 1 Yr. Growth % | -27.47 | -261.8 | 202.76 | -107.66 | 591.61 | |||||
Capital Expenditures, 1 Yr. Growth % | -35.95 | 52.39 | -52.39 | -75.39 | 168.49 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -24.13 | 181.56 | 6.4 | -122.81 | 29 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -27.67 | 203.74 | 5.14 | -131.67 | 15.25 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 18.42 | 10.01 | -4.71 | 19.45 | 25.79 | |||||
Gross Profit, 2 Yr. CAGR % | 13.33 | 5.57 | -28.73 | 0.67 | 61.35 | |||||
EBITDA, 2 Yr. CAGR % | 43.86 | -55.83 | -4.03 | 36.74 | 43.81 | |||||
EBITA, 2 Yr. CAGR % | -45.62 | 29.41 | 333.76 | -15.26 | -31.12 | |||||
EBIT, 2 Yr. CAGR % | -48.06 | 29.05 | 350.39 | -15.08 | -31.51 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -75.42 | 56.2 | 758.82 | -7.01 | -57.56 | |||||
Net Income, 2 Yr. CAGR % | -75.42 | 56.2 | 758.82 | -7.01 | -57.56 | |||||
Normalized Net Income, 2 Yr. CAGR % | -82.63 | 18.84 | 1.11K | -4.85 | -38.5 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -76.7 | 50.74 | 752.82 | -9.44 | -60 | |||||
Accounts Receivable, 2 Yr. CAGR % | 28.28 | -1.07 | -9.94 | 46.44 | 25.08 | |||||
Inventory, 2 Yr. CAGR % | 10.77 | 69.88 | 59 | 8.53 | 8.92 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 5.28 | 4.65 | 7.14 | -1.19 | -11.02 | |||||
Total Assets, 2 Yr. CAGR % | 7.2 | 5.44 | -0.74 | 0.27 | -1.47 | |||||
Tangible Book Value, 2 Yr. CAGR % | 6.11 | 3.76 | -12.41 | -4.79 | 4.14 | |||||
Common Equity, 2 Yr. CAGR % | 6 | 3.67 | -12.41 | -4.83 | 4.04 | |||||
Cash From Operations, 2 Yr. CAGR % | 102.14 | 8.33 | 121.33 | -51.85 | -27.23 | |||||
Capital Expenditures, 2 Yr. CAGR % | 36.92 | -1.2 | -14.83 | -65.77 | -18.71 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 205.51 | 46.16 | 66.03 | -50.74 | -52.94 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 331.75 | 48.22 | 71.05 | -42.29 | -45.62 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 20.54 | 10.6 | 4.43 | 11.25 | 14.19 | |||||
Gross Profit, 3 Yr. CAGR % | 18.56 | 4.31 | -13.8 | -1.2 | 11.58 | |||||
EBITDA, 3 Yr. CAGR % | 63.16 | -47.63 | 37.33 | -18.83 | 88.14 | |||||
EBITA, 3 Yr. CAGR % | -49.35 | 34.6 | 56.34 | 63.75 | 13.44 | |||||
EBIT, 3 Yr. CAGR % | -50.69 | 34.07 | 55.81 | 68.58 | 12.72 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -67.69 | 24.39 | 78.1 | 202.01 | -25.29 | |||||
Net Income, 3 Yr. CAGR % | -67.69 | 24.39 | 78.1 | 202.01 | -25.29 | |||||
Normalized Net Income, 3 Yr. CAGR % | -75.39 | 25.38 | 46.93 | 256.16 | 3.61 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -71.01 | 19.22 | 74.27 | 194.75 | -28.04 | |||||
Accounts Receivable, 3 Yr. CAGR % | 42.44 | 2.41 | 6.74 | 11.86 | 24.81 | |||||
Inventory, 3 Yr. CAGR % | 9.84 | 33.85 | 55.13 | 32.04 | 15.35 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 2.47 | 6.64 | 4.74 | 2.22 | -5.99 | |||||
Total Assets, 3 Yr. CAGR % | 10.75 | 5.05 | 2.78 | 0.47 | -1.76 | |||||
Tangible Book Value, 3 Yr. CAGR % | 14.63 | 1.65 | -3.97 | -5.43 | -3.74 | |||||
Common Equity, 3 Yr. CAGR % | 14.43 | 1.57 | -4.02 | -5.47 | -3.79 | |||||
Cash From Operations, 3 Yr. CAGR % | 36.71 | 87.69 | 52.59 | -27.88 | 17.04 | |||||
Capital Expenditures, 3 Yr. CAGR % | 8.72 | 41.89 | -22.54 | -43.69 | -31.99 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -12.9 | 197.31 | 27.88 | -14.34 | -38.24 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -13.36 | 283.99 | 28.39 | -2.51 | -32.25 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 15.06 | 12.22 | 9.72 | 14.06 | 12.5 | |||||
Gross Profit, 5 Yr. CAGR % | 9.81 | 7.93 | -3.28 | 4.37 | 10.77 | |||||
EBITDA, 5 Yr. CAGR % | 10.18 | -22.19 | 31.96 | 2.05 | 39.88 | |||||
EBITA, 5 Yr. CAGR % | -20.86 | 59.09 | 19.58 | 5.37 | 12.64 | |||||
EBIT, 5 Yr. CAGR % | -21.98 | 56.76 | 19.45 | 5.27 | 12.15 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -31.22 | 71.49 | 19.99 | 10.73 | 0.35 | |||||
Net Income, 5 Yr. CAGR % | -31.22 | 71.49 | 19.99 | 10.73 | 0.35 | |||||
Normalized Net Income, 5 Yr. CAGR % | -45 | 41.57 | 16.95 | 6.39 | 3.71 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -38.79 | 56.8 | 12.13 | 6.8 | -3.27 | |||||
Accounts Receivable, 5 Yr. CAGR % | 22.11 | 5.52 | 18.58 | 18.16 | 13.73 | |||||
Inventory, 5 Yr. CAGR % | 7.76 | 24.12 | 27.36 | 23.08 | 34.67 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 23.25 | 3.28 | 4.31 | 3.43 | -1.87 | |||||
Total Assets, 5 Yr. CAGR % | 12.48 | 5.52 | 6 | 3.11 | 1.06 | |||||
Tangible Book Value, 5 Yr. CAGR % | 10.74 | 5.3 | 2.93 | -0.98 | -0.81 | |||||
Common Equity, 5 Yr. CAGR % | 10.56 | 5.18 | 2.82 | -1.04 | -0.87 | |||||
Cash From Operations, 5 Yr. CAGR % | 33.82 | 5.6 | 65.77 | 8.92 | 13.48 | |||||
Capital Expenditures, 5 Yr. CAGR % | -8.43 | -25.87 | -1.39 | -19.66 | -21.03 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -13.36 | -23.08 | 12.74 | 42.46 | -14.27 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -14.94 | -23.68 | 13.74 | 76.8 | -8.94 |
- Stock Market
- Stocks
- ICCC Stock
- Financials ImmuCell Corporation
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















